Plastic surgery to remove saggy skin from the upper arms is on the rise. The British ­Association of Aesthetic Plastic ...

New research challenges fears about Ozempic weight regain. Cleveland Clinic study of 8,000 patients finds minimal rebound after stopping GLP-1 medications.

Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Peer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

Intermittent fasting and keto burn fat and shift the body to product ketones, but it remains unclear which is more effective.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...